| Primary |
| Stem Cell Transplant |
26.9% |
| Immunosuppression |
14.8% |
| Multiple Myeloma |
13.6% |
| Drug Use For Unknown Indication |
9.9% |
| Allogenic Bone Marrow Transplantation Therapy |
8.6% |
| Cord Blood Transplant Therapy |
5.9% |
| Product Used For Unknown Indication |
4.7% |
| Prophylaxis |
3.0% |
| Immunosuppressant Drug Therapy |
1.9% |
| Bone Marrow Transplant |
1.5% |
| Acute Myeloid Leukaemia |
1.4% |
| Plasma Cell Myeloma |
1.4% |
| Chemotherapy |
1.0% |
| Infection |
1.0% |
| Hyperthermia |
0.8% |
| Transplant |
0.8% |
| Amyloidosis |
0.8% |
| Lymphoma |
0.8% |
| Prophylaxis Against Graft Versus Host Disease |
0.8% |
| Non-hodgkin's Lymphoma |
0.7% |
|
| Sepsis |
13.9% |
| Febrile Neutropenia |
13.8% |
| Vomiting |
11.6% |
| Pyrexia |
8.1% |
| Stomatitis |
7.1% |
| Pneumonia |
6.3% |
| Venoocclusive Liver Disease |
3.7% |
| White Blood Cell Count Decreased |
3.1% |
| Cardiac Failure |
2.9% |
| Interstitial Lung Disease |
2.9% |
| Renal Failure Acute |
2.9% |
| Thrombocytopenia |
2.9% |
| Thrombotic Microangiopathy |
2.9% |
| Mucosal Inflammation |
2.8% |
| Mucous Membrane Disorder |
2.8% |
| Myoclonus |
2.8% |
| C-reactive Protein Increased |
2.6% |
| Respiratory Failure |
2.6% |
| Renal Failure |
2.2% |
| Septic Shock |
2.2% |
|
| Secondary |
| Multiple Myeloma |
32.8% |
| Product Used For Unknown Indication |
10.8% |
| Stem Cell Transplant |
7.8% |
| Drug Use For Unknown Indication |
7.2% |
| Immunosuppression |
5.0% |
| Plasma Cell Myeloma |
4.0% |
| B-cell Lymphoma |
3.9% |
| Mantle Cell Lymphoma |
3.8% |
| Infection Prophylaxis |
3.5% |
| Lymphoma |
3.3% |
| Prophylaxis |
2.9% |
| Non-hodgkin's Lymphoma |
1.9% |
| Allogenic Bone Marrow Transplantation Therapy |
1.9% |
| Febrile Neutropenia |
1.9% |
| Prophylaxis Against Graft Versus Host Disease |
1.9% |
| Cord Blood Transplant Therapy |
1.8% |
| Acute Lymphocytic Leukaemia |
1.7% |
| Amyloidosis |
1.5% |
| Bone Marrow Conditioning Regimen |
1.3% |
| Acute Myeloid Leukaemia |
1.3% |
|
| X-ray Abnormal |
7.6% |
| Acute Myeloid Leukaemia |
7.0% |
| White Blood Cell Count Decreased |
7.0% |
| Myelodysplastic Syndrome |
6.3% |
| Pancytopenia |
5.7% |
| Sepsis |
5.7% |
| Stomatitis |
5.7% |
| Febrile Neutropenia |
5.1% |
| Hepatitis B |
5.1% |
| Septic Shock |
5.1% |
| Interstitial Lung Disease |
4.4% |
| Pulmonary Fibrosis |
4.4% |
| Renal Failure Acute |
4.4% |
| Respiratory Failure |
4.4% |
| Thrombocytopenia |
4.4% |
| Pneumonia |
3.8% |
| Vomiting |
3.8% |
| White Blood Cell Count Increased |
3.8% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.2% |
| Urinary Retention |
3.2% |
|
| Concomitant |
| Multiple Myeloma |
36.8% |
| Drug Use For Unknown Indication |
12.8% |
| Product Used For Unknown Indication |
10.5% |
| Acute Myeloid Leukaemia |
6.9% |
| Acute Lymphocytic Leukaemia |
3.8% |
| Packed Red Blood Cell Transfusion |
3.8% |
| Platelet Transfusion |
3.8% |
| Prophylaxis |
3.6% |
| Pain |
2.5% |
| Infection Prophylaxis |
2.4% |
| Hypertension |
1.7% |
| Plasma Cell Myeloma |
1.7% |
| Blood Product Transfusion |
1.6% |
| Pyrexia |
1.4% |
| Febrile Neutropenia |
1.3% |
| Spinal Fracture |
1.3% |
| Prophylaxis Against Graft Versus Host Disease |
1.3% |
| Convulsion Prophylaxis |
1.1% |
| Bone Lesion |
1.0% |
| Constipation |
0.9% |
|
| Tooth Extraction |
13.4% |
| Weight Decreased |
11.7% |
| Sepsis |
9.1% |
| Osteonecrosis |
7.8% |
| Systemic Candida |
6.8% |
| Wound Drainage |
5.2% |
| Urinary Tract Infection |
4.9% |
| Death |
3.9% |
| Renal Failure |
3.9% |
| Vertebroplasty |
3.9% |
| Vomiting |
3.6% |
| Acute Graft Versus Host Disease |
3.3% |
| Purulent Discharge |
3.3% |
| White Blood Cell Count Decreased |
3.3% |
| Pneumonia |
2.9% |
| Transient Ischaemic Attack |
2.9% |
| Cytomegalovirus Viraemia |
2.6% |
| Renal Impairment |
2.6% |
| Varicella |
2.6% |
| Acute Graft Versus Host Disease In Skin |
2.3% |
|
